- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06784960
Kommunikasjonsstrategier for å øke HPV-vaksinasjonsintensjonen
En klynge randomisert kontrollert prøvetesting kommunikasjonsstrategier for å øke HPV-vaksinasjonsintensjonen: et undersøkelseseksperiment
This research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the Human Papillomavirus (HPV) vaccine, which is highly effective in preventing HPV-related cancers. However, low HPV vaccination rates among adults remain a significant public health challenge. Although randomized controlled trials (RCTs) have demonstrated that interventions can increase vaccine uptake in children, few RCTs have been conducted among adults.
To address this gap, a multidisciplinary investigative team with expertise in communication, medicine, nursing, and behavior-change intervention research will conduct a survey experiment and a cluster randomized controlled trial. First, a national sample of adults ages 18 to 45 who have not received the HPV vaccine or are unsure of their vaccination status will participate in a survey experiment to identify the most promising theory-based messages to strengthen HPV vaccine intentions. The two messages associated with the largest increases in vaccination intentions will then be selected for further testing.
Next, 16 Penn Medicine primary care clinics will participate in a factorial cluster randomized controlled trial to test patient-level and clinic-level interventions designed to increase HPV vaccine uptake. Patient-level interventions will include theory-based text messages and a reminder-only message condition. The clinic-level intervention will provide healthcare providers with feedback on missed opportunities for HPV vaccination and a toolkit to support strong HPV vaccine recommendations.
The study will evaluate whether these interventions increase receipt of the first HPV vaccine among eligible adult patients and whether combining patient-directed messages with the clinic-level intervention further increases HPV vaccination. HPV vaccination will be assessed using Penn Medicine electronic health records and, when needed, patient self-report.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18-45 years old
Exclusion Criteria:
- Under 18 and over 45 years old
- Received HPV vaccine or unsure about receipt
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HPV Message 1 + Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. |
|
Eksperimentell: HPV Message 1 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentell: HPV Message 2 + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentell: HPV Message 2 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentell: HPV Message 3 + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentell: HPV Message 3 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Aktiv komparator: Control Message + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. An attention-matched control text-message condition that does not contain the theory-based HPV vaccination messages being evaluated. |
|
Aktiv komparator: Control Message + No Clinic Intervention
|
An attention-matched control text-message condition that does not contain the theory-based HPV vaccination messages being evaluated. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Aim 1 - Intention to Vaccinate
Tidsramme: Immediately after exposure to the assigned message
|
Assessed using a three-item validated HPV Vaccination Intention Scale. The three items evaluate the participant's intent, plan, and likelihood to receive the HPV vaccine within the next 6 months. Responses for each item were recorded on a 5-point Likert scale. A composite intention score was calculated as the mean of the three items, with total scores ranging from 1 to 5. Higher scores indicate a better outcome (a greater intention to receive the HPV vaccine). |
Immediately after exposure to the assigned message
|
|
Aim 2 - Receipt of HPV Vaccine
Tidsramme: From intervention initiation through 9 months of follow-up
|
Receipt of HPV vaccine during the follow-up period, determined from HPV vaccination documentation in the electronic health record or patient self-report. |
From intervention initiation through 9 months of follow-up
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Patologiske prosesser
- Sykdomsattributter
- Infeksjoner
- Virussykdommer
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- DNA-virusinfeksjoner
- Tumorvirusinfeksjoner
- Patologiske tilstander, tegn og symptomer
- Oppførsel
- Behandlingsoverholdelse og etterlevelse
- Helseatferd
- Avslag på behandling
- Vaksinasjonsnektelse
- Papillomavirusinfeksjoner
- Kommunikasjon
- Vaksinasjonsnøling
Andre studie-ID-numre
- UPCC 02026
- 856892 (Annen identifikator: University of Pennsylvania IRB)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .